Five technology appraisals (TAs) have been issued by NICE and three have been updated, detailing evidence-based recommendations regarding whether the following drugs should be used for the specified indication:
TA463—Cabozantinib for previously treated advanced renal cell carcinoma*
TA464—Bisphosphonates for treating osteoporosis
TA465—Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
TA466—Baricitinib for moderate to severe rheumatoid arthritis*
TA467—Holoclar for treating limbal stem cell deficiency after eye burns
TA160—Alendronate, etidronate, risedronate, raloxifene, and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
TA161—Alendronate, etidronate, risedronate, raloxifene, strontium ranelate, and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
TA190—Pemetrexed for the maintenance treatment of non-small-cell lung cancer.
*only if the company provides the product with the discount agreed in the patient access scheme.
NICE TAs assess the clinical and cost effectiveness of health technologies, such as new pharmaceutical and biopharmaceutical products, as well as procedures, devices, and diagnostic agents. If the TA recommends a treatment as an option, the NHS must make sure it is available within 3 months (unless otherwise specified) of the TA publication date.